Catenaa, Tuesday, July 29, 2025- AstraZeneca has increasing business in the US with 50% revenue expected from the state side by 2030, amidst reports that the UK-listed company might come to Wall Street.
CEO Pascal Soriot on Tuesday said the UK-listed company had many reasons to be in the US, adding that it was “rapidly transferring manufacturing” across the Atlantic so it could serve all US patient needs domestically.
“We have lots of reasons to be here [in the US],” Soriot told the media during an earnings call.
“This country [the US] will represent, we hope, 50% of our revenue by 2030. We have thousands of employees … across the country,” he added.
AstraZeneca has been doubling down on the US market, saying in its second-quarter earnings report on Tuesday that the country was key to its ambition of delivering $80 billion in revenue by the end of the decade.
“We are a global company, but we are certainly, very much, present and rooted in the US,” Soriot said, noting that it plans to soon become self-sufficient there.
The company said last week it plans to invest $50 billion in bolstering its US manufacturing and research capabilities. It marks the latest pharmaceutical firm to ramp up its stateside spending in the wake of US trade tariffs and calls by President Donald Trump to reshore manufacturing.
“Our investment is reflecting our belief in the growth of this country. We want to contribute to this,” Soriot said, noting that he had met with the Trump administration to discuss growth plans within the sector.
“The US really leads in biopharmaceutical innovation these days,” he added, criticizing Europe’s failure to drive development. “Today, very little comes out of Europe.”
